Molecular Partners AG Asset Resilience Ratio
Molecular Partners AG asset resilience ratio. Molecular Partners AG (MOLN) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Molecular Partners AG to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Molecular Partners AG (2015–2025)
Asset resilience ratio of Molecular Partners AG from 2015 to 2025. This chart shows how Molecular Partners AG's Asset Resilience Ratio has changed over time. Read how much debt does Molecular Partners AG carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Molecular Partners AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Molecular Partners AG.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Molecular Partners AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Molecular Partners AG Industry Peers by Asset Resilience Ratio
Compare Molecular Partners AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Molecular Partners AG Asset Resilience Ratio by Year (2015–2025)
Molecular Partners AG asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Molecular Partners AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.19% | CHF10.40 Million ≈ $13.15 Million |
CHF102.11 Million ≈ $129.09 Million |
-43.78pp |
| 2024-12-31 | 53.97% | CHF85.56 Million ≈ $108.18 Million |
CHF158.53 Million ≈ $200.42 Million |
-6.31pp |
| 2023-12-31 | 60.29% | CHF119.58 Million ≈ $151.18 Million |
CHF198.35 Million ≈ $250.77 Million |
-1.18pp |
| 2022-12-31 | 61.47% | CHF161.20 Million ≈ $203.80 Million |
CHF262.26 Million ≈ $331.56 Million |
+26.14pp |
| 2021-12-31 | 35.33% | CHF61.00 Million ≈ $77.12 Million |
CHF172.67 Million ≈ $218.30 Million |
+14.00pp |
| 2020-12-31 | 21.33% | CHF40.00 Million ≈ $50.57 Million |
CHF187.55 Million ≈ $237.11 Million |
+2.87pp |
| 2019-12-31 | 18.46% | CHF19.37 Million ≈ $24.49 Million |
CHF104.94 Million ≈ $132.67 Million |
-- |
| 2018-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF155.16 Million ≈ $196.16 Million |
-- |
| 2017-12-31 | 6.75% | CHF9.74 Million ≈ $12.32 Million |
CHF144.42 Million ≈ $182.59 Million |
-9.81pp |
| 2016-12-31 | 16.56% | CHF30.49 Million ≈ $38.55 Million |
CHF184.10 Million ≈ $232.75 Million |
+7.44pp |
| 2015-12-31 | 9.13% | CHF20.02 Million ≈ $25.31 Million |
CHF219.40 Million ≈ $277.38 Million |
-- |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more